Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Alba M, Fintini D, Sagazio A, et al. American Journal of Physiology-Endocrinology and Metabolism 2006;291:E1290-E1294.
What it found
Mice lacking GHRH that received CJC-1295 daily reached normal body weight and length; dosing every 48 or 72 hours improved growth but did not fully normalise it. Pituitary RNA and growth hormone mRNA rose, with signs that growth hormone-producing cells had multiplied.
Limitations
Genetically GHRH-deficient young mice, a model of growth hormone deficiency rather than normal physiology. Used the albumin-binding (DAC) version.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.